Physician profile
Kelsie Tescher
NPI 1184115685
$2,555.17
in general payments reported to CMS, 2019-2025
22 companies · $922 in 2025
The $922 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $63.01 · 2023: $193 · 2024: $1,378 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.12 | 2022-2025 | |
| Amgen INC. | $320.40 | 2024-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $262.78 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $257.31 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $229.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.06 | 2024-2025 | Jardiance, Synjardy |
| Madrigal Pharmaceuticals | $77.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Glaxosmithkline, LLC. | $76.13 | 2024-2025 | Nucala, Shingrix |
| Daiichi Sankyo INC. | $72.37 | 2022-2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.82 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $64.47 | 2024-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $62.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Actelion Pharmaceuticals US, INC. | $61.55 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $60.76 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $51.85 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $43.33 | 2024 | Skyclarys |
| Boston Scientific Corporation | $41.99 | 2024-2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $32.72 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $31.85 | 2024-2025 | |
| Alkermes, INC. | $29.87 | 2025 | Lybalvi |
| Organon LLC | $15.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsie Tescher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.